Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

36.20USD
17 Oct 2017
Change (% chg)

$0.22 (+0.61%)
Prev Close
$35.98
Open
$35.92
Day's High
$36.33
Day's Low
$35.75
Volume
4,087,213
Avg. Vol
5,122,240
52-wk High
$36.60
52-wk Low
$29.83

Latest Key Developments (Source: Significant Developments)

The Nature's Bounty Co names Mark Gelbert chief scientific officer
Monday, 16 Oct 2017 10:00am EDT 

Oct 16 (Reuters) - The Nature's Bounty Co [RIC:RIC:CRLYNY.UL]::The Nature's Bounty Co. names Mark Gelbert chief scientific officer.Most recently, Gelbert was senior vice president of Global Research and Development and Switch for Pfizer Consumer Healthcare​.  Full Article

FDA approves Pfizer's Lyrica® CR extended-release tablets CV
Thursday, 12 Oct 2017 08:00am EDT 

Oct 12 (Reuters) - Pfizer Inc :Pfizer Inc - ‍U.S. FDA approves Lyrica CR extended-release tablets CV​.Says ‍Lyrica CR did not receive approval for management of fibromyalgia​.Pfizer inc - ‍lyrica cr did not receive approval for management of fibromyalgia​.Pfizer - in PHN study, 73.6% of patients in Lyrica CR group achieved at least 50% improvement in pain intensity compared with 54.6% in placebo group.  Full Article

Nestle has no comment on Pfizer's consumer healthcare business
Wednesday, 11 Oct 2017 03:19am EDT 

Oct 11 (Reuters) - Nestle SA :Nestle declines comment on any interest in Pfizer's consumer healthcare business, says does not comment on rumours as a matter of policy.  Full Article

Pfizer reviewing strategic alternatives for Consumer Healthcare business
Tuesday, 10 Oct 2017 06:45am EDT 

Oct 10 (Reuters) - Pfizer Inc :Pfizer reviewing strategic alternatives for Consumer Healthcare business.Pfizer - engaged Centerview Partners LLC, Guggenheim Securities LLC and Morgan Stanley & Co. LLC as financial advisors for strategic review process​.Pfizer - ‍range of options will be considered, including a full or partial separation of Consumer Healthcare business from pfizer through a spin-off​.  Full Article

‍Moody's says biosimilars market adoption faces hurdles but development continues apace​
Thursday, 28 Sep 2017 11:53am EDT 

Sept 28 (Reuters) - Moody's::‍Moody's says biosimilars market adoption faces hurdles but development continues apace​.Moody's says slow launch of Pfizer's inflectra illustrates hurdles that biosimilar manufacturers face in gaining significant traction in the U.S.‍​.Moody's says potential changes to U.S. Medicare reimbursement could further encourage biosimilar adoption‍​.‍Moody's says among biggest reasons for biosimilars' slow adoption in U.S. is medicare reimburses providers at higher rates for innovator product use.‍Moody's says Medicare reimburses providers at lower rates for switching to the biosimilar from innovator product.‍Moody's says "biosimilar developers still have lots of room for growth, and we expect a number of new approvals over the next 12 to 18 months".  Full Article

Pfizer declares 32-cent fourth-quarter 2017 dividend
Wednesday, 27 Sep 2017 08:30am EDT 

Sept 27 (Reuters) - Pfizer Inc :Pfizer declares 32-cent fourth-quarter 2017 dividend.  Full Article

Merck KGaA's Bavencio drug wins EU approval for Merkel cell carcinoma
Thursday, 21 Sep 2017 03:11am EDT 

Sept 21 (Reuters) - Merck KGaA ::European commission approves Bavencio (avelumab) for metastatic Merkel cell carcinoma.  Full Article

‍Pfizer files lawsuit against Johnson & Johnson​
Wednesday, 20 Sep 2017 09:10am EDT 

Sept 20 (Reuters) - Johnson & Johnson :‍Pfizer says filed suit in U.S. District Court for Eastern District of Pennsylvania against Johnson & Johnson​.Pfizer says suit alleges J&J's "exclusionary" contracts, "anticompetitive" practices have denied U.S. patients access to therapeutic options.Pfizer - suit further claims J&J'S efforts related to remicade by excluding biosimilar competitors violates federal antitrust laws​‍​.Pfizer - suit further claims J&J'S efforts related to remicade by excluding biosimilar competitors violates federal antitrust laws​‍​‍​.  Full Article

Transgene says first patient treated in a phase 1B/2 trial of TG4001
Tuesday, 19 Sep 2017 11:45am EDT 

Sept 19 (Reuters) - TRANSGENE SA ::TRANSGENE: FIRST PATIENT TREATED IN A PHASE 1B/2 TRIAL OF TG4001 IN COMBINATION WITH AVELUMAB IN HPV-POSITIVE CANCERS.‍FIRST RESULTS EXPECTED IN 2018​.  Full Article

Astellas Pharma and Pfizer say positive top-line results from phase 3 prosper trial of XTANDI (enzalutamide)
Thursday, 14 Sep 2017 05:17am EDT 

Sept 14 (Reuters) - Astellas Pharma Inc <4503.T>:Co and Pfizer Inc <<>> announced that the Phase 3 PROSPER trial evaluating XTANDI®(enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) CastrationResistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS) .The preliminary safety analysis of the PROSPER trial appears consistent with the safety profile of XTANDI in previous clinical trials.  Full Article

BRIEF-Pfizer presents results from Phase 2 study of investigational ALK-inhibitor lorlatinib

* Pfizer presents full results from Phase 2 study of next-generation investigational ALK-inhibitor lorlatinib in ALK-positive and ROS1-positive advanced non-small cell lung cancer